DOCSLIB.ORG

A Zic2/Runx2/NOLC1 Signaling Axis Mediates Tumor Growth And

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Zic2/Runx2/NOLC1 Signaling Axis Mediates Tumor Growth And Wu et al. Cell Death and Disease (2021) 12:319 https://doi.org/10.1038/s41419-021-03617-8 Cell Death & Disease ARTICLE Open Access A Zic2/Runx2/NOLC1 signaling axis mediates tumor growth and metastasis in clear cell renal cell carcinoma Chen-Yan Wu 1,LeiLi2,Shi-LuChen1, Xia Yang1, Chris Zhiyi Zhang 3 and Yun Cao 1 Abstract Clear cell renal cell carcinoma (ccRCC) is one of the most common malignancies with rapid growth and high metastasis, but lacks effective therapeutic targets. Here, using public sequencing data analyses, quantitative real-time PCR assay, western blotting, and IHC staining, we characterized that runt-related transcription factor 2 (Runx2) was significantly upregulated in ccRCC tissues than that in normal renal tissues, which was associated with the worse survival of ccRCC patients. Overexpression of Runx2 promoted malignant proliferation and migration of ccRCC cells, and inversely, interfering Runx2 with siRNA attenuates its oncogenic ability. RNA sequencing and functional studies revealed that Runx2 enhanced ccRCC cell growth and metastasis via downregulation of tumor suppressor nucleolar and coiled-body phosphoprotein 1 (NOLC1). Moreover, increased Zic family member 2 (Zic2) was responsible for the upregulation of Runx2 and its oncogenic functions in ccRCC. Kaplan–Meier survival analyses indicated that ccRCC patients with high Zic2/Runx2 and low NOLC1 had the worst outcome. Therefore, our study demonstrates that Zic2/ Runx2/NOLC1 signaling axis promotes ccRCC progression, providing a set of potential targets and prognostic indicators for patients with ccRCC. 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; Introduction molecular characteristics and histological classification, Renal cell carcinoma (RCC), also known as renal ade- clear cell renal cell carcinoma (ccRCC) is the most com- nocarcinoma, is a common malignant tumor arising from mon histological subtype in RCC accounting for nearly the renal tubular epithelial system. In 2019, the cancer 80% of RCC patients3. Although patients with early-stage statistics in United States showed an estimated 73,820 ccRCC can obtain a well therapeutic effect through new diagnoses and 14,770 deaths for RCC. The incidence nephrectomy or nephrectomy-preserving tumor resec- and mortality of RCC are increasing every year1. There are tion, there are still many cases with local recurrence or main causes of RCC, such as smoking, obesity, cadmium distant metastasis. Especially metastatic ccRCC, the effi- exposure, the use of chronic analgesics, cystic kidney cacy of traditional chemical drugs is insignificant because disease, and certain genetic syndromes2. According to of the high drug resistance of ccRCC cells4,5. Therefore, investigating the key oncogenes involved in the aberrant proliferation and metastasis of ccRCC is a valuable goal Correspondence: Chris Zhiyi Zhang ([email protected])or toward revealing the mechanisms of cancer progression Yun Cao ([email protected]) and identifying new therapeutic targets for ccRCC 1 Department of Pathology, State Key Laboratory of Oncology in South China treatment. and Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 510060 Guangzhou, China Runt-related transcription factor (Runx) proteins, 2Department of Clinical Oncology, The University of Hong Kong, Hong Kong, including Runx1, Runx2, and Runx3, are known as tran- China scription factors in the physiological and pathological pro- Full list of author information is available at the end of the article These authors contributed equally: Chen-Yan Wu, Lei Li cesses of the body. Runx2 as a member of the Runx family is Edited by G.-Q. Chen © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a linktotheCreativeCommons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. Official journal of the Cell Death Differentiation Association Wu et al. Cell Death and Disease (2021) 12:319 Page 2 of 11 widely involved in bone formation and osteoblast differ- University Cancer Center (Guangzhou, China). Human entiation6. Furthermore, Runx2 effectively prevented immortalized renal epithelial cell 293T and ccRCC cell apoptosis of intestinal epithelial cells during the develop- lines ACHN, 786-O, SKRC39, and CAKI-1 were pre- ment of Crohn’s disease7. In the last decade, Runx2 has served in our laboratory. All cells were cultured with been shown to be involved in the regulation of cancer DMEM (Gibco) supplemented with 10% fetal bovine progression with dual functions of oncogenic potential and serum (FBS, Gibco) at 37 °C with 5% CO2. When the cells tumor suppressor abilities8,9. Transcriptional inhibition of reached 80–90% confluence, digestion and passage were Runx2 was negatively correlated with aggressive clin- performed with trypsinization. icopathological outcomes, whereas nuclear location of Runx2 promoted metastasis in prostate cancer10.Over- Plasmid construction, RNA interference, and cell expression of Runx2 suppressed osteosarcoma cell growth transfection in vitro11. Runx2 could inhibit p53-dependent apoptosis The coding sequence of Runx2 was obtained by reverse through the functional collaboration with HDAC6 in transcription PCR (RT-PCR) and cloned into pZM02 response to DNA damage12. In addition, increasing evi- vector. The promoter of NOLC1 was also amplified by dences suggested an aggressive role of Runx2 in various RT-PCR and cloned into pGL4.10 luciferase reporter cancers. For instance, high expression of Runx2 was sig- vector. The expressions of Zic2, Runx2, and NOLC1 were nificantly correlated with larger tumor size, lymph node silenced with siRNA oligonucleotides (Table S1). Scram- metastasis, and shorter postoperative survival time of ble RNA was used as a negative control. The culture patients with non-small cell lung cancer13. Repression of medium was changed to fresh DMEM with 10% FBS 24 h Runx2 transcriptional activity blocked the proliferation, before transfection. The plasmids and siRNA oligonu- migration, and invasion of epithelial ovarian carcinoma cleotides were transfected into cancer cells with Lipo- cells14. In-depth studies revealed that Runx2 promoted fectamine 2000 (50 nM, Invitrogen). Transfected cells cancer progression by inducing the epithelial–mesenchymal were cultured at 37 °C with 5% CO2 for 6 h, and then the transition (EMT) progress in breast cancer15, thyroid car- culture medium was replaced by fresh normal medium. cinoma16, and hepatocellular carcinoma (HCC)17.There- The expression levels of target genes were confirmed with fore, dysregulation of Runx2 modulates tumor cell quantitative real-time PCR (qRT-PCR) and western blot proliferation and metastasis, and revealing the underlying at 24 or 36 h after transfection, respectively. mechanism is urgent in the future development of indivi- dual treatments against different types of cancer. However, RNA extraction and qRT-PCR the expression and role of Runx2 in ccRCC are, as yet, Total RNA from fresh tissues or cell lines was extracted unclear. with TRIzol Reagent (Invitrogen). Note that fresh ccRCC In the present study, we clearly characterized the expres- and normal renal tissues were frozen with liquid nitrogen sion and prognosis prediction of Runx2 in ccRCC, and found and grinded until powdered before lysis with TRIzol. that aberrant overexpression of Runx2 was significantly Complementary DNA was synthesized with reverse associated with poor survival of ccRCC patients. Functional transcriptase (Takara) according to the manufacturer’s and mechanism studies revealed that Runx2 was upregulated instruction. The mRNA expression levels of genes were by Zic family member 2 (Zic2) and enhanced ccRCC cell analyzed by qRT-PCR using FastStart Universal SYBR proliferation and migration via transcriptional inhibition of Green Master (Roche) and a Real-Time PCR Detection tumor suppressor nucleolar and coiled-body phosphoprotein System (Roche); 18S rRNA was tested as an internal 1 (NOLC1). Therefore, our findings clearly demonstrate that control. The relative expression level (defined as fold −ΔΔ dysregulation of Zic2/Runx2/NOLC1 signaling promotes change) of the target gene (2 Ct) was normalized to the ccRCC progression. endogenous 18S reference (ΔCt). The primers used were listed in Table S2. Materials and methods Clinical samples and cell lines Western blot Human ccRCC and normal renal tissues were obtained Western blot analysis was performed according to the from ccRCC patients without preoperative chemor- standard protocol18. Human fresh ccRCC/normal renal adiotherapy treatment at Sun Yat-sen University Cancer tissues and cells were lysed with RIPA lysis buffer (Cell Center (Guangzhou, China). Tissue microarray contain- Signaling Technology) supplemented with cocktail pro- ing 301 paired ccRCC and normal renal tissues was tease inhibitor (Roche)
Load more

Recommended publications
  • Jdp2 Downregulates Trp53 Transcription to Promote Leukaemogenesis in the Context of Trp53 Heterozygosity
    Oncogene (2013) 32, 397 --402 & 2013 Macmillan Publishers Limited All rights reserved 0950-9232/13 www.nature.com/onc SHORT COMMUNICATION Jdp2 downregulates Trp53 transcription to promote leukaemogenesis in the context of Trp53 heterozygosity L van der Weyden1, AG Rust1,4, RE McIntyre1,4, CD Robles-Espinoza1, M del Castillo Velasco-Herrera1, R Strogantsev2, AC Ferguson-Smith2, S McCarthy1, TM Keane1, MJ Arends3 and DJ Adams1 We performed a genetic screen in mice to identify candidate genes that are associated with leukaemogenesis in the context of Trp53 heterozygosity. To do this we generated Trp53 heterozygous mice carrying the T2/Onc transposon and SB11 transposase alleles to allow transposon-mediated insertional mutagenesis to occur. From the resulting leukaemias/lymphomas that developed in these mice, we identified nine loci that are potentially associated with tumour formation in the context of Trp53 heterozygosity, including AB041803 and the Jun dimerization protein 2 (Jdp2). We show that Jdp2 transcriptionally regulates the Trp53 promoter, via an atypical AP-1 site, and that Jdp2 expression negatively regulates Trp53 expression levels. This study is the first to identify a genetic mechanism for tumour formation in the context of Trp53 heterozygosity. Oncogene (2013) 32, 397--402; doi:10.1038/onc.2012.56; published online 27 February 2012 Keywords: p53; Jdp2; transposon; heterozygosity; lymphoma; mice INTRODUCTION targeted by transposon insertion events leading to upregulated Genetic alterations of TP53 are frequent events in tumourigenesis Jdp2 expression and a decrease in Trp53 expression levels. Further and promote genomic instability, impair apoptosis, and contribute we illustrate that Jdp2 regulates the Trp53 promoter via an atypical to aberrant self-renewal.1--4 The spectrum of mutations that occur AP-1 binding site.
    [Show full text]
  • A Dissertation Entitled the Androgen Receptor
    A Dissertation entitled The Androgen Receptor as a Transcriptional Co-activator: Implications in the Growth and Progression of Prostate Cancer By Mesfin Gonit Submitted to the Graduate Faculty as partial fulfillment of the requirements for the PhD Degree in Biomedical science Dr. Manohar Ratnam, Committee Chair Dr. Lirim Shemshedini, Committee Member Dr. Robert Trumbly, Committee Member Dr. Edwin Sanchez, Committee Member Dr. Beata Lecka -Czernik, Committee Member Dr. Patricia R. Komuniecki, Dean College of Graduate Studies The University of Toledo August 2011 Copyright 2011, Mesfin Gonit This document is copyrighted material. Under copyright law, no parts of this document may be reproduced without the expressed permission of the author. An Abstract of The Androgen Receptor as a Transcriptional Co-activator: Implications in the Growth and Progression of Prostate Cancer By Mesfin Gonit As partial fulfillment of the requirements for the PhD Degree in Biomedical science The University of Toledo August 2011 Prostate cancer depends on the androgen receptor (AR) for growth and survival even in the absence of androgen. In the classical models of gene activation by AR, ligand activated AR signals through binding to the androgen response elements (AREs) in the target gene promoter/enhancer. In the present study the role of AREs in the androgen- independent transcriptional signaling was investigated using LP50 cells, derived from parental LNCaP cells through extended passage in vitro. LP50 cells reflected the signature gene overexpression profile of advanced clinical prostate tumors. The growth of LP50 cells was profoundly dependent on nuclear localized AR but was independent of androgen. Nevertheless, in these cells AR was unable to bind to AREs in the absence of androgen.
    [Show full text]
  • Regulation of Runx2 Accumulation and Its Consequences
    Regulation of Runx2 Accumulation and Its Consequences Junko Shimazu Submitted in partial fulfillment of the requirement for the degree of Doctor of Philosophy in the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2016 ©2016 Junko Shimazu All Rights Reserved ABSTRACT Regulation of Runx2 Accumulation and Its Consequences Junko Shimazu Osteoblasts are bone-forming cells and therefore they are responsible of the synthesis of type I collagen, the main component of bone matrix. However, there is an apparent disconnect between the regulation of osteoblast differentiation and bone formation since the synthesis of Type I collagen precedes the expression of Runx2, the earliest determinant of osteoblast differentiation. Recently, genetic experiments in the mouse have revealed the existence of an unexpected cross-regulation between bone and other organs. In particular this body of work has highlighted the importance of osteoblasts as endocrine cells to regulate whole-body glucose homeostasis by secretion of a hormone, osteocalcin. However, the fundamental question of why bone regulates glucose homeostasis remained to be answered. Therefore, in my thesis, considering that bone is a metabolically demanding organ that constantly renews itself, I hypothesized that characterizing the connection between the need of glucose as a main nutrient in osteoblasts and bone development will provide a key to deeper understanding of why bone regulates glucose homeostasis. My work shows here that glucose uptake through GLUT1 in osteoblasts is needed for osteoblast differentiation by suppressing the AMPK-dependent activation by phosphorylation at S148 of Smurf1 that targets Runx2 for degradation. I also uncovered the mechanism of action of Smurf1 in this setting.
    [Show full text]
  • Effects of Estrogen Receptor and Wnt Signaling Activation On
    International Journal of Molecular Sciences Article Effects of Estrogen Receptor and Wnt Signaling Activation on Mechanically Induced Bone Formation in a Mouse Model of Postmenopausal Bone Loss 1, , 1, 1 1 Astrid Liedert * y, Claudia Nemitz y, Melanie Haffner-Luntzer , Fabian Schick , Franz Jakob 2 and Anita Ignatius 1 1 Institute of Orhopedic Research and Biomechanics, Trauma Research Center Ulm, University Medical Center Ulm, 89081 Ulm, Germany; [email protected] (C.N.); melanie.haff[email protected] (M.H.-L.); [email protected] (F.S.); [email protected] (A.I.) 2 Orthopaedic Center for Musculoskeletal Research, University of Würzburg, 97074 Würzburg, Germany; [email protected] * Correspondence: [email protected]; Tel.: +49-731-500-55333; Fax: +49-731-500-55302 These authors contributed equally to the study. y Received: 14 September 2020; Accepted: 31 October 2020; Published: 5 November 2020 Abstract: In the adult skeleton, bone remodeling is required to replace damaged bone and functionally adapt bone mass and structure according to the mechanical requirements. It is regulated by multiple endocrine and paracrine factors, including hormones and growth factors, which interact in a coordinated manner. Because the response of bone to mechanical signals is dependent on functional estrogen receptor (ER) and Wnt/β-catenin signaling and is impaired in postmenopausal osteoporosis by estrogen deficiency, it is of paramount importance to elucidate the underlying mechanisms as a basis for the development of new strategies in the treatment of osteoporosis. The present study aimed to investigate the effectiveness of the activation of the ligand-dependent ER and the Wnt/β-catenin signal transduction pathways on mechanically induced bone formation using ovariectomized mice as a model of postmenopausal bone loss.
    [Show full text]
  • Supplementary Information
    Osa et al Supplementary Information Clinical implications of monitoring nivolumab immunokinetics in previously treated non– small cell lung cancer patients Akio Osa, Takeshi Uenami, Shohei Koyama, Kosuke Fujimoto, Daisuke Okuzaki, Takayuki Takimoto, Haruhiko Hirata, Yukihiro Yano, Soichiro Yokota, Yuhei Kinehara, Yujiro Naito, Tomoyuki Otsuka, Masaki Kanazu, Muneyoshi Kuroyama, Masanari Hamaguchi, Taro Koba, Yu Futami, Mikako Ishijima, Yasuhiko Suga, Yuki Akazawa, Hirotomo Machiyama, Kota Iwahori, Hyota Takamatsu, Izumi Nagatomo, Yoshito Takeda, Hiroshi Kida, Esra A. Akbay, Peter S. Hammerman, Kwok-kin Wong, Glenn Dranoff, Masahide Mori, Takashi Kijima, Atsushi Kumanogoh Supplemental Figures 1 – 8 1 Osa et al Supplemental Figure 1. The frequency of nivolumab-bound T cells was maintained in patients who continued treatment. Nivolumab binding in CD8 and CD4 T cells was analyzed at two follow-up points, as indicated, in fresh peripheral blood from three representative cases from protocol 1 that continued treatment. 2 Osa et al Supplemental Figure 2. Long-term follow-up of nivolumab binding to T cells from fresh whole blood. Nivolumab binding was followed up in fresh peripheral blood from an additional case, Pt.7. 3 Osa et al Supplemental Figure 3. Long-term duration of nivolumab binding is due to sustained circulation of residual nivolumab in plasma. (A) PBMCs acquired from Pt.8 and 9 at pretreatment (pre PBMCs) and after a single dose (post 1 PBMCs) were cultured in regular medium without nivolumab (top and middle). Pre PBMCs were also incubated with 10 µg/ml nivolumab in vitro before the cultures were started (bottom). Nivolumab binding status was monitored at the indicated time points.
    [Show full text]
  • RUNX2 Regulates Leukemic Cell Metabolism and Chemotaxis in High-Risk T Cell Acute Lymphoblastic Leukemia
    RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia Filip Matthijssens, … , Pieter Van Vlierberghe, Ksenia Matlawska-Wasowska J Clin Invest. 2021;131(6):e141566. https://doi.org/10.1172/JCI141566. Research Article Oncology Graphical abstract Find the latest version: https://jci.me/141566/pdf The Journal of Clinical Investigation RESEARCH ARTICLE RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia Filip Matthijssens,1,2 Nitesh D. Sharma,3,4 Monique Nysus,3,4 Christian K. Nickl,3,4 Huining Kang,4,5 Dominique R. Perez,4,6 Beatrice Lintermans,1,2 Wouter Van Loocke,1,2 Juliette Roels,1,2 Sofie Peirs,1,2 Lisa Demoen,1,2 Tim Pieters,1,2 Lindy Reunes,1,2 Tim Lammens,2,7 Barbara De Moerloose,2,7 Filip Van Nieuwerburgh,8 Dieter L. Deforce,8 Laurence C. Cheung,9,10 Rishi S. Kotecha,9,10 Martijn D.P. Risseeuw,2,11 Serge Van Calenbergh,2,11 Takeshi Takarada,12 Yukio Yoneda,13 Frederik W. van Delft,14 Richard B. Lock,15 Seth D. Merkley,5 Alexandre Chigaev,4,6 Larry A. Sklar,4,6 Charles G. Mullighan,16 Mignon L. Loh,17 Stuart S. Winter,18 Stephen P. Hunger,19 Steven Goossens,1,2,20 Eliseo F. Castillo,5 Wojciech Ornatowski,21 Pieter Van Vlierberghe,1,2 and Ksenia Matlawska-Wasowska3,4 1Department of Biomolecular Medicine, Ghent University, Ghent, Belgium. 2Cancer Research Institute Ghent (CRIG), Ghent, Belgium. 3Department of Pediatrics, Division of Hematology-Oncology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.
    [Show full text]
  • BMP9 Prevents Induction of Osteopontin in JNK-Inactivated
    International Journal of Biochemistry and Cell Biology 116 (2019) 105614 Contents lists available at ScienceDirect International Journal of Biochemistry and Cell Biology journal homepage: www.elsevier.com/locate/biocel BMP9 prevents induction of osteopontin in JNK-inactivated osteoblasts via Hey1-Id4 interaction T ⁎ Joji Kusuyamaa,b, , Changhwan Seonga,c, Toshiaki Nakamurad, Tomokazu Ohnishia, Muhammad Subhan Amira,c,e, Kaori Shimaf, Ichiro Sembaf, Kazuyuki Noguchid, Tetsuya Matsuguchia a Department of Oral Biochemistry, Field of Developmental Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan b Section on Integrative Physiology and Metabolism, Joslin Diabetes Center, Department of Medicine, Harvard Medical School, One Joslin Place, Boston, MA, 02215, USA c Department of Oral and Maxillofacial Surgery, Field of Oral and Maxillofacial Rehabilitation, Kagoshima University Graduate School of Medical and Dental Sciences, 8- 35-1 Sakuragaoka, Kagoshima, 890-8544, Japan d Department of Periodontology, Field of Oral and Maxillofacial Rehabilitation, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan e Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Airlangga University, Campus A UNAIR, JL. Mayjen Professor Doktor Moestopo No. 47, Pacar Kembang, Tambaksari, Kota SBY, Surabaya, Jawa Timur, 60132, Indonesia f Department of Oral Pathology, Field of Oncology, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan ARTICLE INFO ABSTRACT Keywords: Osteopontin (OPN) is an osteoblast-derived secretory protein that plays a role in bone remodeling, osteoblast BMP9 responsiveness, and inflammation. We recently found that osteoblast differentiation is type-specific, with con- Osteopontin ditions of JNK inactivation inducing osteoblasts that preferentially express OPN (OPN-type).
    [Show full text]
  • The Role of P53-Induced Mir-145A in Senescence and Osteogenesis of Mesenchymal Stem Cells
    The Role of p53-induced miR-145a in Senescence and Osteogenesis of Mesenchymal Stem Cells Chao Xia Shanghai Jiaotong University School of Medicine Xinhua Hospital Tianyuan Jiang Shanghai Jiaotong University School of Medicine Xinhua Hospital Yonghui Wang Shanghai Jiaotong University School of Medicine Xinhua Hospital Xiaoting Chen Shanghai Jiaotong University School of Medicine Xinhua Hospital Yan Hu Shanghai Jiaotong University School of Medicine Xinhua Hospital Yanhong Gao ( [email protected] ) https://orcid.org/0000-0003-4173-4855 Research Keywords: microRNAs, osteogenesis, senescence, mesenchymal stem cells, p53, Cbfb Posted Date: March 17th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-17497/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/21 Abstract Background: The osteogenic differentiation capacity of senescent bone marrow mesenchymal stem cells (MSCs) is diminished. However, little is known about the mechanisms. p53 not only regulates cellular senescence but also, as a negative regulator, is involved in bone formation. This study investigated the molecular mechanism of p53 in cellular senescence and osteogenesis. Methods: The expression of p53 and its downstream gene p21 were measured during cellular senescence and osteogenesis differentiation of primary bone marrow MSCs. Then miR-145a was picked out from those p53-induced miRNAs as its expression change in bone marrow MSCs senescence and osteogenesis induced by H2O2 and BMP-9, respectively. The function of p53 induced miR-145a was analyzed by transfected with miRNA mimic in osteogenic differentiation of MSCs. Western blot and luciferase reporter assay were used for validating the target of miR-145a.
    [Show full text]
  • Estrogen Promotes Mandibular Condylar Fibrocartilage
    www.nature.com/scientificreports OPEN Estrogen Promotes Mandibular Condylar Fibrocartilage Chondrogenesis and Inhibits Received: 27 November 2017 Accepted: 18 May 2018 Degeneration via Estrogen Published: xx xx xxxx Receptor Alpha in Female Mice Jennifer L. Robinson 1,3, Paola Soria2, Manshan Xu2, Mark Vrana1, Jefrey Luchetti1, Helen H. Lu3, Jing Chen2 & Sunil Wadhwa2 Temporomandibular joint degenerative disease (TMJ-DD) is a chronic form of TMJ disorder that specifcally aficts people over the age of 40 and targets women at a higher rate than men. Prevalence of TMJ-DD in this population suggests that estrogen loss plays a role in the disease pathogenesis. Thus, the goal of the present study was to determine the role of estrogen on chondrogenesis and homeostasis via estrogen receptor alpha (ERα) during growth and maturity of the joint. Young and mature WT and ERαKO female mice were subjected to ovariectomy procedures and then given placebo or estradiol treatment. The efect of estrogen via ERα on fbrocartilage morphology, matrix production, and protease activity was assessed. In the young mice, estrogen via ERα promoted mandibular condylar fbrocartilage chondrogenesis partly by inhibiting the canonical Wnt signaling pathway through upregulation of sclerostin (Sost). In the mature mice, protease activity was partly inhibited with estrogen treatment via the upregulation and activity of protease inhibitor 15 (Pi15) and alpha-2- macroglobulin (A2m). The results from this work provide a mechanistic understanding of estradiol on TMJ growth and homeostasis and can be utilized for development of therapeutic targets to promote regeneration and inhibit degeneration of the mandibular condylar fbrocartilage. Temporomandibular joint degenerative disease (TMJ-DD) is marked by degradation and premature calcifcation of the extracellular matrix (ECM) of the articular mandibular condylar fbrocartilage.
    [Show full text]
  • Identification of Shared and Unique Gene Families Associated with Oral
    International Journal of Oral Science (2017) 9, 104–109 OPEN www.nature.com/ijos ORIGINAL ARTICLE Identification of shared and unique gene families associated with oral clefts Noriko Funato and Masataka Nakamura Oral clefts, the most frequent congenital birth defects in humans, are multifactorial disorders caused by genetic and environmental factors. Epidemiological studies point to different etiologies underlying the oral cleft phenotypes, cleft lip (CL), CL and/or palate (CL/P) and cleft palate (CP). More than 350 genes have syndromic and/or nonsyndromic oral cleft associations in humans. Although genes related to genetic disorders associated with oral cleft phenotypes are known, a gap between detecting these associations and interpretation of their biological importance has remained. Here, using a gene ontology analysis approach, we grouped these candidate genes on the basis of different functional categories to gain insight into the genetic etiology of oral clefts. We identified different genetic profiles and found correlations between the functions of gene products and oral cleft phenotypes. Our results indicate inherent differences in the genetic etiologies that underlie oral cleft phenotypes and support epidemiological evidence that genes associated with CL/P are both developmentally and genetically different from CP only, incomplete CP, and submucous CP. The epidemiological differences among cleft phenotypes may reflect differences in the underlying genetic causes. Understanding the different causative etiologies of oral clefts is
    [Show full text]
  • Impact of RUNX2 on Drug-Resistant Human Pancreatic Cancer Cells with P53 Mutations
    Ozaki et al. BMC Cancer (2018) 18:309 https://doi.org/10.1186/s12885-018-4217-9 REVIEWARTICLE Open Access Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations Toshinori Ozaki1*†, Meng Yu2†, Danjing Yin3, Dan Sun4, Yuyan Zhu4, Youquan Bu5 and Meixiang Sang3 Abstract Background: Despite the remarkable advances in the early diagnosis and treatment, overall 5-year survival rate of patients with pancreatic cancer is less than 10%. Gemcitabine (GEM), a cytidine nucleoside analogue and ribonucleotide reductase inhibitor, is a primary option for patients with advanced pancreatic cancer; however, its clinical efficacy is extremely limited. This unfavorable clinical outcome of pancreatic cancer patients is at least in part attributable to their poor response to anti-cancer drugs such as GEM. Thus, it is urgent to understand the precise molecular basis behind the drug-resistant property of pancreatic cancer and also to develop a novel strategy to overcome this deadly disease. Review: Accumulating evidence strongly suggests that p53 mutations contribute to the acquisition and/or maintenance of drug-resistant property of pancreatic cancer. Indeed, certain p53 mutants render pancreatic cancer cells much more resistant to GEM, implying that p53 mutation is one of the critical determinants of GEM sensitivity. Intriguingly, runt-related transcription factor 2 (RUNX2) is expressed at higher level in numerous human cancers such as pancreatic cancer andosteosarcoma,indicatingthat,inadditiontoits pro-osteogenic role, RUNX2 has a pro-oncogenic potential. Moreover, a growing body of evidence implies that a variety of miRNAs suppress malignant phenotypes of pancreatic cancer cells including drug resistance through the down-regulation of RUNX2.
    [Show full text]
  • Retinoblastoma Binding Protein-1 (RBP1) Is a Runx2 Coactivator and Promotes Osteoblastic Differentiation BMC Musculo- Skeletal Disorders 2010, 11:104
    Monroe et al. BMC Musculoskeletal Disorders 2010, 11:104 http://www.biomedcentral.com/1471-2474/11/104 RESEARCH ARTICLE Open Access RetinoblastomaResearch article binding protein-1 (RBP1) is a Runx2 coactivator and promotes osteoblastic differentiation David G Monroe*, John R Hawse, Malayannan Subramaniam and Thomas C Spelsberg Abstract Background: Numerous transcription factors are involved in the establishment and maintenance of the osteoblastic phenotype, such as Runx2, osterix and Dlx5. The transcription factor retinoblastoma binding protein-1 (RBP1) was recently identified as an estrogen regulated gene in an osteosarcoma cell model. Since the function of RBP1 in osteoblastic differentiation and mineralization is unknown, we investigated the role of RBP1 in these processes. Methods: To create a cell model with suppressed RBP1 expression, primary calvarial osteoblasts were infected with a shRNA lentiviral vector specific for mouse RBP1 (CalOB-ΔRBP1) or a scrambled control shRNA lentivirus (CalOB-Control). Stable cell lines were generated and their mineralization potential was determined using osteoblastic differentiation medium, Alizarin Red staining, and quantitative PCR (QPCR) analyses. Runx2 coactivation by RBP1 was determined through the use of transient transfection assays. Results: Stable expression of the RBP1 shRNA lentivirus in CalOB-ΔRBP1 cells resulted in a 65-70% suppression of RBP1 expression. Osteoblastic mineralization assays demonstrated that suppression of RBP1 results in a potent delay in osteoblastic nodule formation in the CalOB-ΔRBP1 cells with a concomitant decrease in the expression of the osteogenic transcription factors Runx2 and osterix, along with decreases in BMP2, alkaline phosphatase, osteocalcin and bone sialoprotein. Regulation of Runx2 expression by RBP1 was shown to be mediated through the proximal P2 Runx2 promoter.
    [Show full text]